A phase I trial of intralesional rV-tricom vaccine in the treatment of malignant melanoma

Human Gene Therapy

Volumn 12, Issue 11, 2001, Pages 1459-1480

  Kaufman, H L ^a   DeRaffele, G ^a   Divito, J ^a   Horig H ^a   Lee, D ^a   Panicali, D ^a   Voulo, M ^a  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; RECOMBINANT VACCINE; RV TRICOM; VACCINIA VACCINE;

ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG FORMULATION; DRUG INFORMATION; DRUG MANUFACTURE; EVALUATION; GENE THERAPY; HUMAN; INFORMED CONSENT; MEDICAL RECORD; MELANOMA; PATIENT INFORMATION; PATIENT SELECTION; QUALITY OF LIFE; RISK; STATISTICAL ANALYSIS; TREATMENT PLANNING;

ADOLESCENT; ADULT; CLINICAL PROTOCOLS; CLINICAL TRIALS, PHASE I; FEMALE; HUMANS; INFORMED CONSENT; INJECTIONS, INTRALESIONAL; LYMPH NODES; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; SKIN NEOPLASMS; STATISTICS; TIME FACTORS; VACCINES, SYNTHETIC;

VACCINIA;

EID: 0034824727     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303401750298616     Document Type: Article

References (58)

1. Cancer statistics. 1999
2. Conservative surgical management of superficially invasive cutaneous melanoma
3. Tumor thickness as a guide to surgical management of clinical stage I melanoma patients
4. Optimal resection margin for cutaneous malignant melanoma
5. Elective node dissection: Pros and cons
6. The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm)
7. Efficacy of lymph node dissection in 2,347 patients with clinical stage I malignant melanoma
8. Recent advances in the care of the patient with malignant melanoma
9. Technical details of intra-operative lymphatic mapping for early stage melanoma
10. Effect of surgical treatment of stage IV melanoma
11. Cutaneous melanoma
12. Radiation therapy of malignant melanoma: Experience with high individual treatment doses
13. RTOG 83-05: A randomized trial evaluating fraction size in external beam radiation therapy in treatment of melanoma
14. Preclinical studies, experimental therapeutics, and clinical management of advanced melanoma
15. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, Vinblastine, dacarbazine(CVD) and biotherapy using interleukin-2 and interferon-alpha
16. Effective combination chem/hormonal therapy for malignant melanoma: Experience with three consecutive trials
17. Interferon alfa-2b adjuvant therapy of high risk resected cutaneous melanoma: The Eastern Cooperative Group Trial EST 1684
18. Postsurgical adjuvant therapy for melanoma. Evaluation of a 3 year randomized trial with recombinant interferon-alpha after 4 to 5 years of follow up
19. The role of interferon alpha in the treatment of metastatic melanoma
20. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon-alfa and chemotherapy
21. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients
22. Combination therapy with interleukin-2 alpha-interferon for the treatment of patients of advanced cancer
23. Randomized phase trial of treatment with high dose interleukin-2 either alone or in combination with interferon alpha-2a in patients with advanced melanoma
24. Phase study of high dose interleukin-2 IIlymphokine activated killer cells in patients with metastatic malignant melanoma
25. Metastatic malignant mela-noma treated with combined bolus and continuous infusion inter-leukin-2 and lymphokine-activated killer cells
26. Phase I study of high dose continuous infusion recombinant interleukin-2 and autologous lymphokine activated killer cells in patients with metastatic or un-resectable malignant melanoma and renal cell carcinoma
27. A phase II study of high dose continuous infusion interleukin-2 with lymphokine activated killer cells
28. Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study
29. Use of tumor-infiltrating lymphocytes and interleukin-2 in the im-munotherapy of patients with metastatic melanoma: A preliminary report
30. Prospective randomized trial of high dose interleukin-2 alone or in conjunction with lymphokine activated killer cells for the treatment of patients with advanced cancer
31. The modified group C experience-phase III randomized trials of IL-2/LAK in advanced renal cell carcinoma advanced melanoma
32. Interleukin-2 high dose cisplatin in patients with metastatic melanoma: A pilot study
33. A multi-institutional phase trial of intensive combination chemoimmunotherapy for meta-static melanoma
34. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2B
35. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
36. Recombinant anticancer vaccines
37. Do human cancers express shared protective antigens? Or the necessity of remembrance of things past
38. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimula-tory molecule B7
39. CD28 mediated signalling co-stimulates murine T cells and prevents induction of anergy in T cell clones
40. + T cells by B7-transfected melanoma cells
41. Rejection of MHC class-transfected tumor cells required induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules
42. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection the establishment of a memory response
43. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity
44. A reassessment of the role of B7-1 expression in tumor rejection
45. T cell activation pathways: B7, LFA-3, ICAM-1 shape unique T cell profiles
46. Costimulatory requirements of naïve CD41T cells: ICAM-1 or B7-1 can costimulate naïve CD41 T. cell activation but both are required for optimum response
47. CD28: CTLA-4 have opposing effects of the response of T cells to stimulation
48. Expression of MHC class II and 1 and B7-1-and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells
49. B7-mediated costimula-tionthe immune response
50. Is CTLA-4 a master switch for peripheral T cell tolerance?
51. Enhancement of antitu-mor immunity by CTLA-4 blockade
52. The admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor associated antigen results in enhanced specific T-cell responses and antitumor immunity
53. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules
54. A phase I. trial of intra-lesional rV-B7.1 vaccine in the treatment of malignant melanoma
55. A triad of costimulatory molecules synergize to amplify T-cell activation
56. Enhanced activation of T-cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules
57. Reliability validity of the functional assessment of cancer therapy-breast quality-of-life instrument
58. Functional assessment of cancer therapy (FACT-G): Non-response to individual questions